Molecular Partners AG MOLN.OQ, MOLN.O is expected to show no change in quarterly revenue when it reports results on March 12 for the period ending December 31 2025
LSEG's mean analyst estimate for Molecular Partners AG is for a loss of 29 rappen per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Molecular Partners AG is $13.31, about 171.7% above its last closing price of $4.90
This summary was machine generated March 10 at 11:03 GMT. All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)